Discussing GLP-1 Costs & Insurance with Family and Providers

    By Trimi Medical Team8 min read

    GLP-1 medication is an investment in your health, but the cost can create tension in relationships and budgets. Whether you need to discuss the expense with a partner, justify the cost to yourself, or navigate insurance coverage, having the right framing and scripts makes these conversations easier.

    Discussing Cost with Your Partner/Spouse

    Presenting the Investment

    "I want to talk about investing in my health with GLP-1 medication. Compounded versions are available for $99-125 per month. I know that is a line item in our budget, but I want to show you why I think it is worth it. My weight is contributing to [specific health issues], and treating those conditions is going to cost more long term than preventing them now."

    The Cost Offset Argument

    "Here is what I have been thinking about costs. On GLP-1, I am eating significantly less, which reduces our grocery bill. I will likely reduce or eliminate [blood pressure medication/diabetes medication/other medications] over time. And if I can avoid the long-term costs of diabetes, heart disease, or joint replacement, this medication pays for itself many times over."

    Discussing with Your Provider

    Asking About Affordable Options

    "I am interested in GLP-1 therapy but cost is a concern. Are there compounded versions available? I have seen options starting at $99 per month for semaglutide and $125 for tirzepatide. Can you prescribe compounded formulations, or can you refer me to a provider who does?"

    Navigating Insurance

    • Check formulary: Call your insurance to ask if GLP-1 medications are covered under your plan
    • Prior authorization: Many plans require prior authorization. Your provider submits documentation of medical necessity.
    • Appeal denials: If denied, ask your provider to submit an appeal with documentation of your BMI, comorbidities, and failed weight loss attempts
    • Consider compounded: If insurance will not cover brand-name medications, compounded versions from providers like Trimi offer significant savings

    Making the Financial Case

    Consider the full financial picture of obesity-related health costs:

    • Annual obesity-related healthcare costs: Average $1,861 more than normal-weight individuals
    • Diabetes treatment: Average $9,601 per year in medical costs
    • Knee replacement: $30,000-50,000 per knee
    • Cardiovascular event: Average hospitalization cost exceeds $20,000
    • GLP-1 prevention: $99-125/month ($1,188-1,500/year) to potentially avoid all of the above

    Affordable Treatment from Trimi

    Trimi removes the cost barrier. Compounded semaglutide is just $99/month and compounded tirzepatide is $125/month, a fraction of brand-name costs. No insurance required. Visit our treatment page to start.

    Frequently Asked Questions

    Is compounded GLP-1 as effective as brand-name?

    Compounded GLP-1 medications contain the same active ingredient as brand-name versions. They are prepared by licensed compounding pharmacies under FDA oversight. Many patients achieve identical results at a fraction of the cost.

    Can I use HSA or FSA to pay for GLP-1?

    Yes. GLP-1 medications prescribed by a provider for a medical condition are typically eligible for HSA and FSA reimbursement. Check with your plan administrator for specifics.

    What if my partner does not support the expense?

    Frame it as a health investment, not a vanity expense. Show them the cost comparison with treating obesity-related diseases. If needed, identify budget areas to offset the cost (reduced grocery spending on GLP-1 often covers much of the medication cost).

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading